FDA Approves Tzield for Children Ages 1+ With Stage 2 Type 1 Diabetes | KarmActive ✓ FDA Approval Expanded to Children Ages 1+ FDA Approves Tzield for Children Ages 1+ With Stage 2 Type 1 Diabetes First disease-modifying therapy approved to delay disease progression in the youngest patients The U.S. Food and Drug Administration approved an expanded indication for Tzield (teplizumab-mzwv) to delay the progression from stage 2 to stage 3 type